Vyant Bio, Inc. Common Stock
VYNT
VYNTは2023年5月12日に上場廃止となりました。
概要： Vyant Bio Inc incorporates biology and data science to improve drug discovery for complex neurodevelopmental and neurodegenerative disorders. The company's central nervous system drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning. The company's platform is designed to: 1) elucidate disease pathophysiology; 2) formulate key therapeutic hypotheses; 3) identify and validate drug targets, cellular assays, and biomarkers to guide candidate molecule selection; and 4) guide clinical trial patient selection and trial design. The majority of revenue is earned in the United States.
従業員数： 8
ニュース
VYNTに関する最近のニュース記事はまだ届いていません。